Fertility startups are moving beyond disease screening to sell polygenic trait predictions for embryos — including IQ, height, ADHD risk, and appearance — by combining whole‑genome sequencing with consumer genomics pipelines. These products claim measurable shifts (single‑digit IQ point gains, reduced disease probabilities) despite major scientific uncertainty about prediction, transferability from adults to embryos, and environmental interactions.
— If commercial trait selection scales, it will force policy, ethical, and inequality debates about reproductive choice, regulation, and the distributional effects of genetic advantage.
EditorDavid
2026.03.07
60% relevant
This article shows the commercialization of cutting‑edge biological interventions (Sumitomo Pharma's Amchepry and Cuorips' ReHeart) reaching the market under conditional approval—paralleling the broader trend of turning radical genetic/biotech capabilities into consumer/medical products and raising the same questions about access, oversight, and ethical normalization.
Johann Kurtz
2026.03.06
92% relevant
The article cites startups (Heliospect) that screen and rank embryos by polygenic scores for predicted intelligence and charge large sums to implant top candidates — a direct example of commercial embryo‑selection services described by the existing idea.
2026.03.05
100% relevant
Startup names and events in the article: Genomic Prediction’s embryo genotyping, Nucleus offering trait predictions from forwarded raw data, and Herasight claiming a 6–9 point IQ predictor and improved disease‑risk scores.
← Back to All Ideas